UP!
|
Formerly called
|
Galapagos Genomics NV |
|---|---|
|
Type
|
Naamloze vennootschap |
| Traded as | Euronext: GLPG NASDAQ: GLPG |
| Industry | Pharmaceutical |
| Founded | 1999 |
| Headquarters | Mechelen, Belgium |
|
Key people
|
Onno van de Stolpe (CEO), Raj Parekh (Chairman) |
| Products | filgotinib; GLPG1205; GLPG0778 |
| Revenue | €151.6 million (2016) |
| Profit | €54.0 million (2016) |
| Total assets | €1,083 million (end 2016) |
| Total equity | €758.7 million (end 2016) |
|
Number of employees
|
508 (end 2016) |
| Website | www |
Galapagos NV (formerly known as Galapagos Genomics) is a Belgo-Dutch pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville and Zagreb. The CEO is the Dutchman Onno van de Stolpe.
Currently it is developing drugs against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.
Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.
Coordinates: 51°03′19″N 4°27′08″E / 51.05528°N 4.45222°E / 51.05528; 4.45222
| 2016-06-17 | Reiterated Rating | Credit Suisse | Hold | $48.00 |
| 2016-06-17 | Reiterated Rating | Credit Suisse Group AG | Hold | $48.00 |
| 2016-05-02 | Reiterated Rating | Morgan Stanley | Buy | $89.00 |
| 2016-04-30 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-04-08 | Boost Price Target | Morgan Stanley | $89.00 to $92.00 | |
| 2016-03-06 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-01-25 | Downgrade | Goldman Sachs | Buy to Neutral | |
| 2016-01-25 | Downgrade | Goldman Sachs Group Inc. | Buy to Neutral | |
| 2015-12-17 | Boost Price Target | Bryan Garnier & Cie | Buy | $52.00 to $64.00 |
| 2015-12-17 | Boost Price Target | Bryan, Garnier & Co | Buy | $52.00 to $64.00 |
| 2015-12-08 | Upgrade | KBC Securities | Buy | |
| 2015-09-28 | Downgrade | Credit Suisse | Outperform to Neutral | $62.00 to $46.00 |
| 2015-09-25 | Reiterated Rating | Cowen and Company | Buy | |
| 2015-06-08 | Initiated Coverage | Credit Agricole | Outperform | $61.00 |
| 2015-06-08 | Initiated Coverage | Nomura | Buy | $73.00 |
| 2015-06-08 | Initiated Coverage | Cowen and Company | Outperform | |
| 2015-06-08 | Initiated Coverage | Credit Suisse | Outperform | $61.00 |
| 2015-06-08 | Initiated Coverage | Morgan Stanley | Overweight | $73.00 |
| 2015-06-08 | Initiated Coverage | Credit Agricole SA | Outperform | $61.00 |
| 2015-06-08 | Initiated Coverage | Nomura Holdings Inc. | Buy | $73.00 |
| 2016-06-17 | Reiterated Rating | Credit Suisse | Hold | $48.00 |
| 2016-06-17 | Reiterated Rating | Credit Suisse Group AG | Hold | $48.00 |
| 2016-05-02 | Reiterated Rating | Morgan Stanley | Buy | $89.00 |
| 2016-04-30 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-04-08 | Boost Price Target | Morgan Stanley | $89.00 to $92.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In GLPG 69 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| FMR LLC | 3.72M |
| EcoR1 Capital, LLC | 3.20M |
| BlackRock Inc. | 0.48M |
| WELLINGTON MANAGEMENT CO LLP | 0.46M |
| Finepoint Capital LP | 0.38M |
| CITADEL ADVISORS LLC | 0.36M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 0.33M |
| Hudson Bay Capital Management LP | 0.32M |
| GREAT POINT PARTNERS LLC | 0.31M |
| RENAISSANCE TECHNOLOGIES LLC | 0.30M |
| DEUTSCHE BANK AG\ | 0.29M |
| TANG CAPITAL MANAGEMENT LLC | 0.22M |
| Newtyn Management, LLC | 0.18M |
| MORGAN STANLEY | 0.18M |
| GREENLIGHT CAPITAL INC | 0.15M |
UM